CD274 and cancer: After Champiat et al. had introduced the concept of hyperprogression (HP) in a retrospective study of cancer patients receiving PD-1/PD-L1 inhibitors [12], several groups assessed the phenomenon and proposed different criteria for its definition, resulting in notable variations in HPD rates (Table 1).